ClinicalTrials.gg

Acute Pain clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,076 studies for Acute Pain across more than 10 countries. 168 are recruiting or about to start. 694 of them are mainly about Acute Pain (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 3,108 studies for Acute Pain. How that becomes 1,073 here

This page counts the studies the registry files under Acute Pain, and those it files under no condition that list Acute Painthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 3,108Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −168List Acute Pain as a condition, but the registry did not file them under itMost often written as “Postoperative Pain, Acute” (77), “Post Operative Pain, Acute” (40), and “Acute Pain Due to Trauma” (10). The registry filed them under other conditions only, most often Pain, Postoperative (152) and Agnosia (22).
  3. −1,867Match it another way197 name it in the title, 27 in a keyword, and 1,643 by a synonym or other text the search reads.
  4. 1,073The count on this page15 of them list Acute Pain in their own words; the registry filed them under no condition.

Status

Completed
684
Status unknown
111
Recruiting
103
Not yet recruiting
59
Terminated
51
Withdrawn
40

Phase

Phase 4
157
Phase 3
114
Phase 2
114
Phase 1
49
Early Phase 1
12

Where

United States
352
Turkey
158
Canada
61
Egypt
40
France
39
Italy
25

Who develops what

Add Acute Pain to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 10 companies, 9 with this as their studies’ main aim; 3 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Laboratorios Silanes S.A. de C.V., Ache Laboratorios Farmaceuticos and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TramadolRecent, repeated
Evidence
  • NCT07880392 · Ache Laboratorios Farmaceuticos S.A. · Phase 3 · live · comparator · “Tramal®” · registered Oct 2026
  • NCT06215859 · Viatris Inc. · Phase 3 · comparator · “Tramadol” · registered Dec 2023
  • NCT06215820 · Viatris Inc. · Phase 3 · comparator · “Tramadol” · registered Dec 2023
  • NCT05995912 · Laboratorios Liomont · Phase 2 · comparator · “Tramadol” · registered Aug 2023
  • NCT04812860 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “Tramadol hydrochloride ER” · registered Mar 2021
Johnson & Johnson37% of its industry studiesUS: off-patent, 12 generics marketed34 studies
AcetaminophenRecent, repeated
Evidence
  • NCT07807644 · Grünenthal GmbH · Phase 2 · live · comparator · “Hydrocodone bitartrate/ acetaminophen (HB/APAP)” · registered Sep 2026
  • NCT07102459 · Latigo Biotherapeutics · Phase 2 · comparator · “Active Comparator: HB/APAP” · registered Jul 2025
  • NCT06619847 · Vertex Pharmaceuticals Incorporated · Phase 2 · comparator · “HB/APAP” · registered Sep 2024
  • NCT05558410 · Vertex Pharmaceuticals Incorporated · Phase 3 · comparator · “HB/APAP” · registered Sep 2022
  • NCT05553366 · Vertex Pharmaceuticals Incorporated · Phase 3 · comparator · “HB/APAP” · registered Sep 2022
Johnson & Johnson29% of its industry studiesUS: off-patent, 109 generics marketed35 studies
HydrocodoneRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07807644 · Grünenthal GmbH · Phase 2 · live · comparator · “Hydrocodone bitartrate/ acetaminophen (HB/APAP)” · registered Sep 2026
  • NCT06619847 · Vertex Pharmaceuticals Incorporated · Phase 2 · comparator · “HB/APAP” · registered Sep 2024
  • NCT05558410 · Vertex Pharmaceuticals Incorporated · Phase 3 · comparator · “HB/APAP” · registered Sep 2022
  • NCT05553366 · Vertex Pharmaceuticals Incorporated · Phase 3 · comparator · “HB/APAP” · registered Sep 2022
  • NCT05034952 · Vertex Pharmaceuticals Incorporated · Phase 2 · comparator · “HB/APAP” · registered Aug 2021
Teva Pharmaceutical Industries, Ltd.33% of its industry studies24 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Product DNN.63.18.040☆ Track1 live phase-3 study: NCT07880392Ache Laboratorios Farmaceuticos S.A.
IbuprofenApproved: US · EU☆ Track1 live phase-3 study: NCT07225634aft pharmaceuticals ltd
dexibuprofenPhase 4 trial recorded☆ Track1 live phase-3 study: NCT07930559Aponia Laboratories, Inc.

The 3 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.LY4515100 · Eli Lilly and Company · Phase 2 main aimNCT07511816 A Study of LY4515100 in Participants With Pain Following Third Molar Removal — primary endpoint: Change from Baseline in Self-Reported Pain Intensity · 212 enrolled
  • Mar 2027 est.Product DNN.63.18.040 · Ache Laboratorios Farmaceuticos S.A. · Phase 3 main aimvs TramadolNCT07880392 Efficacy and Safety of DNN.63.18.040 for the Treatment of Moderate to Severe Pain — primary endpoint: Total Pain Relief Score (TOTPAR6) · 370 enrolled
  • Mar 2027 est.Ibuprofen · aft pharmaceuticals ltd · Phase 3 main aimNCT07225634 A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain — primary endpoint: The incidence of treatment-emergent adverse events (TEAEs) associated with exposure to Combogesic® IV in pediatric patients · 60 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Acute Pain studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 7 open · Opioids 6 open · NSAIDs 3 open · Inhaled anesthetics 1 open · Corticosteroids 1 open

Coming up

70studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger. 21 (20%) take children under 18. 13 (13%) are for women only and 0 (0%) for men only; 24 (23%) take healthy volunteers.

Recruiting studies that take each age, of 103
AgeWomenMen
1011 (11%)11 (11%)
1885 (83%)74 (72%)
3085 (83%)72 (70%)
4084 (82%)72 (70%)
5080 (78%)70 (68%)
6572 (70%)66 (64%)
7557 (55%)53 (51%)
8546 (45%)42 (41%)

Across all 1,076 studies, recruiting or not: 50% stop at 75 or younger and 38% at 65; 17% take children; 10% are for women only and 2% for men only; 28% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Acute Pain studies take

Of 84 phase 4 interventional studies under Acute Pain, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 17 mo3–17 · 33 studies——
Phase 210 mo5–23 · 40 studies——
Phase 2/313 mo10–20 · 14 studies——
Phase 314 mo7–25 · 54 studies11 mo6–15 · 29 studies20 mo10–27 · 25 studies
Phase 419 mo9–32 · 84 studies—20 mo11–32 · 79 studies
Interventional, no phase11 mo5–23 · 431 studies—12 mo5–23 · 425 studies
Observational15 mo5–41 · 74 studies—15 mo5–41 · 72 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,076. Browse all 1,076 → or search them.